Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Phys Rev Lett ; 106(5): 057201, 2011 Feb 04.
Artigo em Inglês | MEDLINE | ID: mdl-21405425

RESUMO

The temperature-pressure phase diagram for both the crystal and magnetic structures of LaCrO(3) perovskite has been mapped out by in situ neutron-diffraction experiments under pressure. The system offers the opportunity to study the evolution of magnetic order, spin direction, and magnetic moment on crossing the orthorhombic-rhombohedral phase boundary. Moreover, a microscopic model of the superexchange interaction has been developed on the basis of the crystal structure obtained in this work to account for the behavior of T(N) under high pressure.

2.
Bone Marrow Transplant ; 15(3): 349-51, 1995 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-7541268

RESUMO

The use of recombinant human granulocyte-stimulating factor (G-CSF) has been shown to effectively accelerate granulocytic recovery after autologous bone marrow transplantation (BMT) in adults. The experience, however, is limited in children. We evaluated the hematopoietic reconstitution in 41 consecutive children undergoing autologous BMT for hematologic malignancies (21 acute lymphoblastic leukemia, five non-Hodgkin's lymphoma) and solid tumours (seven neuroblastoma, two brain tumor, three Ewing's sarcoma, two Wilms' tumor, one rhabdomyosarcoma). Their ages ranged from 2 to 16 years (mean 7.2 years). rhG-CSF was given at a dose of 10 micrograms/kg/day i.v. in a 2h infusion from day +1 until +28 or until the absolute neutrophil count (ANC) was > 1 x 10(9)/L. These patients were compared with a similar historical control group of 38 children who did not receive rhG-CSF after autologous BMT. The number of cells infused was similar in both groups. At the dose and schedule used in the present study, rhG-CSF was well tolerated and no side-effects were observed. The number of cell infused was similar in both groups. At the dose and schedule used in the present study, rhG-CSF was well tolerated and no side-effects were observed. Our data show that rhG-CSF accelerates engraftment and reduces the number of febrile days and antibiotic use. Furthermore, patients who were treated had less infections.


Assuntos
Transplante de Medula Óssea , Fator Estimulador de Colônias de Granulócitos/uso terapêutico , Neoplasias/terapia , Adolescente , Antibacterianos/uso terapêutico , Infecções Bacterianas/complicações , Criança , Pré-Escolar , Feminino , Humanos , Infusões Intravenosas , Linfoma não Hodgkin/sangue , Linfoma não Hodgkin/terapia , Masculino , Neoplasias/sangue , Leucemia-Linfoma Linfoblástico de Células Precursoras/sangue , Leucemia-Linfoma Linfoblástico de Células Precursoras/terapia , Transplante Autólogo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA